Johnson & Johnson (NYSE:JNJ) said today that the European Commission approved its acquisition of Swiss biotech Actelion. The regulatory nod was the last approval needed to complete the company’s transaction.
The U.S. healthcare giant added that it expects the settlement of the $30 billion all-cash tender offer on June 16.
Get the full story at our sister site, Drug Delivery Business News.
The post Johnson & Johnson wins last regulatory nod needed for Actelion acquisition appeared first on MassDevice.